Biochemical Changes in the Niche Following Tumor Cell Invasion

Overview

Journal J Cell Biochem

Specialties Biochemistry
Cell Biology

Date 2016 Dec 17

PMID 27982511

Citations 3

Authors

A M Decker

F C Cackowski

Y Jung

R S Taichman

Affiliations

Soon will be listed here.

Abstract

Metastatic cancer is the leading cause of all cancer related deaths. Prostate cancer (PCa) metastasizes preferentially to the bone marrow, specifically within the endosteal niche. Endosteal cells secrete homing molecules that may recruit PCa cells to the bone marrow. Once there, the biochemical signature of this niche regulates PCa fate including cellular dormancy or cell cycle arrest, reactivation and resistance to chemotherapeutics. Growth factors, interleukins, adhesion molecules, as well as extra-cellular matrix proteins can collectively change the phenotype of PCa cells. Understanding the biochemical signature of endosteal niche parasitism by PCa is imperative for the establishment of new and innovative therapeutic strategies. This review seeks to summarize these important niche signatures and the potential therapeutic approaches to target metastatic PCa within the bone marrow hematopoietic stem cell (HSC) niche. J. Cell. Biochem. 118: 1956-1964, 2017. © 2016 Wiley Periodicals, Inc.

Citing Articles

Cancer Cell De-Differentiation: Plasticity-Driven Stratagem For Tumor Metastasis and Recurrence.

El Marsafy S, Larghero J Curr Stem Cell Res Ther. 2022; 18(1):54-61.

PMID: 35676837 DOI: 10.2174/1574888X17666220608101852.

Adrenergic Blockade Promotes Maintenance of Dormancy in Prostate Cancer Through Upregulation of GAS6.

Decker A, Decker J, Jung Y, Cackowski F, Daignault-Newton S, Morgan T Transl Oncol. 2020; 13(7):100781.

PMID: 32361123 PMC: 7191848. DOI: 10.1016/j.tranon.2020.100781.

Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer.

Lee C, Decker A, Cackowski F, Taichman R Cell Biol Toxicol. 2019; 36(2):115-130.

PMID: 31250347 PMC: 6933113. DOI: 10.1007/s10565-019-09483-7.

References

Erlebacher A, Derynck R . Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol. 1996; 132(1-2):195-210. PMC: 2120709. DOI: 10.1083/jcb.132.1.195. View

Ren B, Yee K, Lawler J, Khosravi-Far R . Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta. 2006; 1765(2):178-88. DOI: 10.1016/j.bbcan.2005.11.002. View

Yumoto K, Eber M, Wang J, Cackowski F, Decker A, Lee E . Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow. Sci Rep. 2016; 6:36520. PMC: 5098246. DOI: 10.1038/srep36520. View

Gundem G, Van Loo P, Kremeyer B, Alexandrov L, Tubio J, Papaemmanuil E . The evolutionary history of lethal metastatic prostate cancer. Nature. 2015; 520(7547):353-357. PMC: 4413032. DOI: 10.1038/nature14347. View

Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M . ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009; 23(16):1882-94. PMC: 2725946. DOI: 10.1101/gad.1824809. View

Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T . Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett. 2000; 473(2):161-4. DOI: 10.1016/s0014-5793(00)01520-9. View

Kobayashi A, Okuda H, Xing F, Pandey P, Watabe M, Hirota S . Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208(13):2641-55. PMC: 3244043. DOI: 10.1084/jem.20110840. View

Pawar S, Demetriou M, Nagle R, Bowden G, Cress A . Integrin alpha6 cleavage: a novel modification to modulate cell migration. Exp Cell Res. 2007; 313(6):1080-9. PMC: 1905853. DOI: 10.1016/j.yexcr.2007.01.006. View

Denham J, Joseph D, Lamb D, Spry N, Duchesne G, Matthews J . Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3.... Lancet Oncol. 2014; 15(10):1076-89. DOI: 10.1016/S1470-2045(14)70328-6. View

10.

Jung Y, Decker A, Wang J, Lee E, Kana L, Yumoto K . Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget. 2016; 7(18):25698-711. PMC: 5041937. DOI: 10.18632/oncotarget.8365. View

11.

Venkatraman L, Chia S, Narmada B, White J, Bhowmick S, Dewey Jr C . Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1. Biophys J. 2012; 103(5):1060-8. PMC: 3433618. DOI: 10.1016/j.bpj.2012.06.050. View

12.

Hall C, Dai J, van Golen K, Keller E, Long M . Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res. 2006; 66(17):8648-54. DOI: 10.1158/0008-5472.CAN-06-1544. View

13.

Soki F, Koh A, Jones J, Kim Y, Dai J, Keller E . Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem. 2014; 289(35):24560-72. PMC: 4148880. DOI: 10.1074/jbc.M114.571620. View

14.

Taichman R, Patel L, Bedenis R, Wang J, Weidner S, Schumann T . GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One. 2013; 8(4):e61873. PMC: 3634826. DOI: 10.1371/journal.pone.0061873. View

15.

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-22. PMC: 3090685. DOI: 10.1016/S0140-6736(10)62344-6. View

16.

Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G . ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 2001; 61(5):1890-5. View

17.

van der Toom E, Verdone J, Pienta K . Disseminated tumor cells and dormancy in prostate cancer metastasis. Curr Opin Biotechnol. 2016; 40:9-15. PMC: 4975648. DOI: 10.1016/j.copbio.2016.02.002. View

18.

Ajani J, DAmico T, Almhanna K, Bentrem D, Chao J, Das P . Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(10):1286-1312. DOI: 10.6004/jnccn.2016.0137. View

19.

Chan J, Stampfer M, Giovannucci E, Gann P, Ma J, Wilkinson P . Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998; 279(5350):563-6. DOI: 10.1126/science.279.5350.563. View

20.

Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B . Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2011; 379(9810):39-46. PMC: 3671878. DOI: 10.1016/S0140-6736(11)61226-9. View